David L Earnest

US Patent:

20090163551, Jun 25, 2009

Filed:

Jun 13, 2007

Appl. No.:

12/308163

Inventors:

David Lewis Earnest - Morristown NJ, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/4439
A61K 31/404

US Classification:

514338, 514415

Abstract:

This invention relates to methods for treating, preventing and/or managing gastric injury, e.g., NSAID-induced gastric injury in a subject including administering to the subject tegaserod, alone or in combination with a proton pump inhibitor. Also provided are compositions and kits for use in methods of the invention.

US Patent:

20090199860, Aug 13, 2009

Filed:

Apr 8, 2004

Appl. No.:

11/666345

Inventors:

Mark Kress - Westport CT, US
David Earnest - Los Angeles CA, US

International Classification:

A41G 5/00
B05B 11/06

US Classification:

132201, 222633

Abstract:

An improved applicator for hair building cosmetic fibers, powders and particles uses a gentle stream of gas to suspend the fibers and waft them onto the user's scalp. A low pressure, low velocity gas stream directed downwards into a mass of fibers in a closed container suspends them. The suspended fibers exit through a small orifice connected with a passageway ending in a nozzle. The suspended fibers are propelled from the bulb in a directed fashion to settle naturally in a controlled area. If a rubber bulb is used to supply air to suspend the fibers, a user can gently squeeze the bulb to allow controlled puffs of air and fibers to waft onto controlled regions of the scalp. A valve arrangement can be operated to provide an air stream to remove excess deposited fibers from regions of the scalp.

US Patent:

20090221665, Sep 3, 2009

Filed:

Dec 20, 2006

Appl. No.:

12/086656

Inventors:

David Lewis Earnest - Morristown NJ, US

International Classification:

A61K 31/405
A61K 31/22

US Classification:

514415, 514551

Abstract:

The present invention relates to a combination of a 5-HT4 receptor agonist and a cholinesterase inhibitor and pharmaceutical compositions and formulations containing the combination. The pharmaceutical combination may be employed for the treatment of altered gastrointestinal motility, sensitivity, secretion or abdominal disorders. The dosage is preferably oral. The preferred 5-HTreceptor agonist is tegaserod.

US Patent:

6677328, Jan 13, 2004

Filed:

Oct 18, 2000

Appl. No.:

09/691496

Inventors:

Carroll Wayne Allen - Chatham NJ
Thomas Albert Brasitus - Olympia Fields IL
David Lewis Earnest - Tuscon AZ
Gerald Leigh Messerschmidt - Mendham NJ

Assignee:

Novartis Corp. - New York City NY
University of Chicago - Chicago IL
University of Arizona - Tucson AZ

International Classification:

A61K 3156

US Classification:

514182, 514169, 424489, 424490, 424451, 424472

Abstract:

Method for the prevention of colonic adenomas in mammals at risk of developing them by administering to such mammals an effective colonic adenoma preventive amount of ursodiol or a pharmaceutically acceptable salt conjugation product thereof.